Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly

Tsui Mai Kao, Szu Min Hsieh, Hsiang Chi Kung, Yi Chien Lee, Kuo Chin Huang, Li Min Huang, Feng Yee Chang, Ning Chi Wang, Yung Ching Liu, Wen Sen Lee, Hsingjin Eugene Liu, Chin I. Chen, Chien Hui Chen

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We conducted a multi-center, randomized and laboratory-blinded clinical trial with subgroup analyses, involving adults aged greater than 60 years old (range 61-86 years old), to investigate the immunogenicity and the potential factors affecting the immune response of a monovalent, unadjuvanted, inactivated, split-virus vaccine. A total of 107 subjects were randomized to receive 15 and 30μg of hemagglutinin antigen in a 1:1 ratio. The immunogenicity was detected through hemagglutination inhibition (HAI) test of serum obtained before and 3 weeks after vaccination. By 3 weeks after vaccination, HAI titer ≥1:40 was observed in 75.5% and 81.1% of participants receiving 15 and 30μg of hemagglutinin antigen, respectively. Positive seroconversion was observed in 71.7% and 81.1% of recipients of the 15 and the 30μg, respectively. The GMTs increased by a factor of 10.7 and 17.4 in the groups of 15 and 30μg, respectively. This study indicated that one dose of 15μg hemagglutinin antigen without adjuvant induced protective immune response in the majority of elderly. Multivariate logistic regression analyses showed that gender, age and diabetes were statistically significant factors affecting the seroprotection rate (p=0.04, 0.01 and 0.01, respectively) and seroconversion rate (p=0.01, 0.01 and 0.01, respectively).

Original languageEnglish
Pages (from-to)6159-6163
Number of pages5
JournalVaccine
Volume28
Issue number38
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Hemagglutinins
Pandemics
pandemic
influenza
Human Influenza
Vaccination
hemagglutinins
vaccination
immune response
Antigens
seroconversion
dosage
antigens
Hemagglutination Inhibition Tests
Immunologic Factors
Hemagglutination
hemagglutination inhibition test
Vaccines
hemagglutination
Logistic Models

Keywords

  • 2009 Pandemic influenza A (H1N1)
  • Immune response
  • Vaccination

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Kao, T. M., Hsieh, S. M., Kung, H. C., Lee, Y. C., Huang, K. C., Huang, L. M., ... Chen, C. H. (2010). Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. Vaccine, 28(38), 6159-6163. https://doi.org/10.1016/j.vaccine.2010.07.026

Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. / Kao, Tsui Mai; Hsieh, Szu Min; Kung, Hsiang Chi; Lee, Yi Chien; Huang, Kuo Chin; Huang, Li Min; Chang, Feng Yee; Wang, Ning Chi; Liu, Yung Ching; Lee, Wen Sen; Liu, Hsingjin Eugene; Chen, Chin I.; Chen, Chien Hui.

In: Vaccine, Vol. 28, No. 38, 08.2010, p. 6159-6163.

Research output: Contribution to journalArticle

Kao, TM, Hsieh, SM, Kung, HC, Lee, YC, Huang, KC, Huang, LM, Chang, FY, Wang, NC, Liu, YC, Lee, WS, Liu, HE, Chen, CI & Chen, CH 2010, 'Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly', Vaccine, vol. 28, no. 38, pp. 6159-6163. https://doi.org/10.1016/j.vaccine.2010.07.026
Kao, Tsui Mai ; Hsieh, Szu Min ; Kung, Hsiang Chi ; Lee, Yi Chien ; Huang, Kuo Chin ; Huang, Li Min ; Chang, Feng Yee ; Wang, Ning Chi ; Liu, Yung Ching ; Lee, Wen Sen ; Liu, Hsingjin Eugene ; Chen, Chin I. ; Chen, Chien Hui. / Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. In: Vaccine. 2010 ; Vol. 28, No. 38. pp. 6159-6163.
@article{8978c1a36a5e49e387c8c661186552ce,
title = "Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly",
abstract = "We conducted a multi-center, randomized and laboratory-blinded clinical trial with subgroup analyses, involving adults aged greater than 60 years old (range 61-86 years old), to investigate the immunogenicity and the potential factors affecting the immune response of a monovalent, unadjuvanted, inactivated, split-virus vaccine. A total of 107 subjects were randomized to receive 15 and 30μg of hemagglutinin antigen in a 1:1 ratio. The immunogenicity was detected through hemagglutination inhibition (HAI) test of serum obtained before and 3 weeks after vaccination. By 3 weeks after vaccination, HAI titer ≥1:40 was observed in 75.5{\%} and 81.1{\%} of participants receiving 15 and 30μg of hemagglutinin antigen, respectively. Positive seroconversion was observed in 71.7{\%} and 81.1{\%} of recipients of the 15 and the 30μg, respectively. The GMTs increased by a factor of 10.7 and 17.4 in the groups of 15 and 30μg, respectively. This study indicated that one dose of 15μg hemagglutinin antigen without adjuvant induced protective immune response in the majority of elderly. Multivariate logistic regression analyses showed that gender, age and diabetes were statistically significant factors affecting the seroprotection rate (p=0.04, 0.01 and 0.01, respectively) and seroconversion rate (p=0.01, 0.01 and 0.01, respectively).",
keywords = "2009 Pandemic influenza A (H1N1), Immune response, Vaccination",
author = "Kao, {Tsui Mai} and Hsieh, {Szu Min} and Kung, {Hsiang Chi} and Lee, {Yi Chien} and Huang, {Kuo Chin} and Huang, {Li Min} and Chang, {Feng Yee} and Wang, {Ning Chi} and Liu, {Yung Ching} and Lee, {Wen Sen} and Liu, {Hsingjin Eugene} and Chen, {Chin I.} and Chen, {Chien Hui}",
year = "2010",
month = "8",
doi = "10.1016/j.vaccine.2010.07.026",
language = "English",
volume = "28",
pages = "6159--6163",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "38",

}

TY - JOUR

T1 - Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly

AU - Kao, Tsui Mai

AU - Hsieh, Szu Min

AU - Kung, Hsiang Chi

AU - Lee, Yi Chien

AU - Huang, Kuo Chin

AU - Huang, Li Min

AU - Chang, Feng Yee

AU - Wang, Ning Chi

AU - Liu, Yung Ching

AU - Lee, Wen Sen

AU - Liu, Hsingjin Eugene

AU - Chen, Chin I.

AU - Chen, Chien Hui

PY - 2010/8

Y1 - 2010/8

N2 - We conducted a multi-center, randomized and laboratory-blinded clinical trial with subgroup analyses, involving adults aged greater than 60 years old (range 61-86 years old), to investigate the immunogenicity and the potential factors affecting the immune response of a monovalent, unadjuvanted, inactivated, split-virus vaccine. A total of 107 subjects were randomized to receive 15 and 30μg of hemagglutinin antigen in a 1:1 ratio. The immunogenicity was detected through hemagglutination inhibition (HAI) test of serum obtained before and 3 weeks after vaccination. By 3 weeks after vaccination, HAI titer ≥1:40 was observed in 75.5% and 81.1% of participants receiving 15 and 30μg of hemagglutinin antigen, respectively. Positive seroconversion was observed in 71.7% and 81.1% of recipients of the 15 and the 30μg, respectively. The GMTs increased by a factor of 10.7 and 17.4 in the groups of 15 and 30μg, respectively. This study indicated that one dose of 15μg hemagglutinin antigen without adjuvant induced protective immune response in the majority of elderly. Multivariate logistic regression analyses showed that gender, age and diabetes were statistically significant factors affecting the seroprotection rate (p=0.04, 0.01 and 0.01, respectively) and seroconversion rate (p=0.01, 0.01 and 0.01, respectively).

AB - We conducted a multi-center, randomized and laboratory-blinded clinical trial with subgroup analyses, involving adults aged greater than 60 years old (range 61-86 years old), to investigate the immunogenicity and the potential factors affecting the immune response of a monovalent, unadjuvanted, inactivated, split-virus vaccine. A total of 107 subjects were randomized to receive 15 and 30μg of hemagglutinin antigen in a 1:1 ratio. The immunogenicity was detected through hemagglutination inhibition (HAI) test of serum obtained before and 3 weeks after vaccination. By 3 weeks after vaccination, HAI titer ≥1:40 was observed in 75.5% and 81.1% of participants receiving 15 and 30μg of hemagglutinin antigen, respectively. Positive seroconversion was observed in 71.7% and 81.1% of recipients of the 15 and the 30μg, respectively. The GMTs increased by a factor of 10.7 and 17.4 in the groups of 15 and 30μg, respectively. This study indicated that one dose of 15μg hemagglutinin antigen without adjuvant induced protective immune response in the majority of elderly. Multivariate logistic regression analyses showed that gender, age and diabetes were statistically significant factors affecting the seroprotection rate (p=0.04, 0.01 and 0.01, respectively) and seroconversion rate (p=0.01, 0.01 and 0.01, respectively).

KW - 2009 Pandemic influenza A (H1N1)

KW - Immune response

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=77955661281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955661281&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.07.026

DO - 10.1016/j.vaccine.2010.07.026

M3 - Article

C2 - 20659517

AN - SCOPUS:77955661281

VL - 28

SP - 6159

EP - 6163

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 38

ER -